Press Releases Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			After market 02:11:18 am
10.96 ^USD	-18.48%		10.93	-0.32%

07:39pm	Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says	MT
05:37pm	Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Iovance Biotherapeutics: Q1 Earnings Snapshot	10/05	AQ
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates	10/05	AQ
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024	01/05	AQ
Iovance Biotherapeutics to Present at Upcoming Conferences	30/04	AQ
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting	25/04	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - April 19, 2024	22/04	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	20/04	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	25/03	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	23/03	AQ
Iovance Biotherapeutics to Present at Upcoming Conferences	04/03	AQ
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer	04/03	AQ
Iovance Biotherapeutics to Present at Upcoming Conferences	02/03	AQ
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	29/02	AQ
Iovance Biotherapeutics: Q4 Earnings Snapshot	29/02	AQ
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	29/02	AQ
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024	22/02	AQ
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI for Advanced Melanoma	21/02	AQ
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI(TM) (lifileucel) for Advanced Melanoma	21/02	AQ
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock	20/02	AQ
Novel immunotherapy approved for melanoma	20/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Press Releases

Filters